The Use of Cannabinoids for Insomnia in Daily Life: Naturalistic Study.
insomnia
linear mixed-effects
medicinal cannabis
symptom management
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
27 10 2021
27 10 2021
Historique:
received:
12
11
2020
accepted:
27
07
2021
revised:
10
05
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Insomnia is a prevalent condition that presents itself at both the symptom and diagnostic levels. Although insomnia is one of the main reasons individuals seek medicinal cannabis, little is known about the profile of cannabinoid use or the perceived benefit of the use of cannabinoids in daily life. We conducted a retrospective study of medicinal cannabis users to investigate the use profile and perceived efficacy of cannabinoids for the management of insomnia. Data were collected using the Strainprint app, which allows medicinal cannabis users to log conditions and symptoms, track cannabis use, and monitor symptom severity pre- and postcannabis use. Our analyses examined 991 medicinal cannabis users with insomnia across 24,189 tracked cannabis use sessions. Sessions were analyzed, and both descriptive statistics and linear mixed-effects modeling were completed to examine use patterns and perceived efficacy. Overall, cannabinoids were perceived to be efficacious across all genders and ages, and no significant differences were found among product forms, ingestion methods, or gender groups. Although all strain categories were perceived as efficacious, predominant indica strains were found to reduce insomnia symptomology more than cannabidiol (CBD) strains (estimated mean difference 0.59, SE 0.11; 95% CI 0.36-0.81; adjusted P<.001) and predominant sativa strains (estimated mean difference 0.74, SE 0.16; 95% CI 0.43-1.06; adjusted P<.001). Indica hybrid strains also presented a greater reduction in insomnia symptomology than CBD strains (mean difference 0.52, SE 0.12; 95% CI 0.29-0.74; adjusted P<.001) and predominant sativa strains (mean difference 0.67, SE 0.16; 95% CI 0.34-1.00; adjusted P=.002). Medicinal cannabis users perceive a significant improvement in insomnia with cannabinoid use, and this study suggests a possible advantage with the use of predominant indica strains compared with predominant sativa strains and exclusively CBD in this population. This study emphasizes the need for randomized placebo-controlled trials assessing the efficacy and safety profile of cannabinoids for the treatment of insomnia.
Sections du résumé
BACKGROUND
Insomnia is a prevalent condition that presents itself at both the symptom and diagnostic levels. Although insomnia is one of the main reasons individuals seek medicinal cannabis, little is known about the profile of cannabinoid use or the perceived benefit of the use of cannabinoids in daily life.
OBJECTIVE
We conducted a retrospective study of medicinal cannabis users to investigate the use profile and perceived efficacy of cannabinoids for the management of insomnia.
METHODS
Data were collected using the Strainprint app, which allows medicinal cannabis users to log conditions and symptoms, track cannabis use, and monitor symptom severity pre- and postcannabis use. Our analyses examined 991 medicinal cannabis users with insomnia across 24,189 tracked cannabis use sessions. Sessions were analyzed, and both descriptive statistics and linear mixed-effects modeling were completed to examine use patterns and perceived efficacy.
RESULTS
Overall, cannabinoids were perceived to be efficacious across all genders and ages, and no significant differences were found among product forms, ingestion methods, or gender groups. Although all strain categories were perceived as efficacious, predominant indica strains were found to reduce insomnia symptomology more than cannabidiol (CBD) strains (estimated mean difference 0.59, SE 0.11; 95% CI 0.36-0.81; adjusted P<.001) and predominant sativa strains (estimated mean difference 0.74, SE 0.16; 95% CI 0.43-1.06; adjusted P<.001). Indica hybrid strains also presented a greater reduction in insomnia symptomology than CBD strains (mean difference 0.52, SE 0.12; 95% CI 0.29-0.74; adjusted P<.001) and predominant sativa strains (mean difference 0.67, SE 0.16; 95% CI 0.34-1.00; adjusted P=.002).
CONCLUSIONS
Medicinal cannabis users perceive a significant improvement in insomnia with cannabinoid use, and this study suggests a possible advantage with the use of predominant indica strains compared with predominant sativa strains and exclusively CBD in this population. This study emphasizes the need for randomized placebo-controlled trials assessing the efficacy and safety profile of cannabinoids for the treatment of insomnia.
Identifiants
pubmed: 34704957
pii: v23i10e25730
doi: 10.2196/25730
pmc: PMC8581757
doi:
Substances chimiques
Cannabinoids
0
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25730Informations de copyright
©Nirushi Kuhathasan, Luciano Minuzzi, James MacKillop, Benicio N Frey. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 27.10.2021.
Références
Int J Drug Policy. 2013 Nov;24(6):511-6
pubmed: 24095000
Sleep Med Rev. 2014 Dec;18(6):477-87
pubmed: 24726015
J Integr Med. 2020 Sep;18(5):416-424
pubmed: 32758396
J Psychoactive Drugs. 2018 Apr-Jun;50(2):95-104
pubmed: 29064777
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Science. 2016 Jun 3;352(6290):1182
pubmed: 27257247
Addict Behav. 2015 Nov;50:178-81
pubmed: 26151582
Cent Nerv Syst Agents Med Chem. 2011 Sep 1;11(3):189-96
pubmed: 21919868
Plant Sci. 2019 Jul;284:67-72
pubmed: 31084880
Sleep Med. 2017 Oct;38:122-129
pubmed: 29031746
Curr Psychiatry Rep. 2017 Apr;19(4):23
pubmed: 28349316
J Clin Ethics. 2016 Winter;27(4):308-321
pubmed: 28001138
Health Rep. 2019 Jun 19;30(6):3-13
pubmed: 31216047
Nature. 2014 Mar 27;507(7493):407-8
pubmed: 24670737
Cannabis Cannabinoid Res. 2018 Oct 01;3(1):203-212
pubmed: 30426073
Sleep Med Rev. 2002 Apr;6(2):97-111
pubmed: 12531146
Front Plant Sci. 2019 Jan 09;9:1969
pubmed: 30687364
J Pain Res. 2016 Sep 30;9:735-744
pubmed: 27757048
JAMA. 2015 Jun 23-30;313(24):2491-3
pubmed: 26103034
J Altern Complement Med. 2014 Oct;20(10):787-91
pubmed: 25191852
Yale J Biol Med. 2020 Jun 29;93(2):251-264
pubmed: 32607086
Front Plant Sci. 2019 Jun 14;10:697
pubmed: 31263468
Sleep. 2008 Apr;31(4):473-80
pubmed: 18457234
J Clin Psychopharmacol. 2004 Jun;24(3):305-13
pubmed: 15118485
J Cannabis Res. 2020 Jul 17;2(1):21
pubmed: 33526118
J Headache Pain. 2018 May 24;19(1):37
pubmed: 29797104
Medicines (Basel). 2018 Jul 11;5(3):
pubmed: 29997343
Front Mol Neurosci. 2020 Jul 22;13:125
pubmed: 32774241
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Int J Mol Sci. 2021 Jan 14;22(2):
pubmed: 33466734
Chest. 2015 Apr;147(4):1179-1192
pubmed: 25846534
J Cannabis Res. 2019 Jun 7;1(1):3
pubmed: 33526091
Biomed Res Int. 2018 Dec 4;2018:1691428
pubmed: 30627539
Compr Psychiatry. 2020 Oct;102:152188
pubmed: 32653594
PLoS One. 2015 Aug 26;10(8):e0133292
pubmed: 26308334
Lancet. 2012 Mar 24;379(9821):1129-41
pubmed: 22265700
Sci Rep. 2019 Feb 25;9(1):2712
pubmed: 30804402
Int J Epidemiol. 2011 Dec;40(6):1431-7
pubmed: 22158659
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1420-7
pubmed: 18514375
Front Pharmacol. 2018 Aug 28;9:916
pubmed: 30210337
Cannabis Cannabinoid Res. 2016 Jan 01;1(1):44-46
pubmed: 28861479
Curr Biol. 2020 Jan 6;30(1):R8-R9
pubmed: 31910378
Exp Clin Psychopharmacol. 2019 Aug;27(4):383-401
pubmed: 31120284
Sci Rep. 2018 Mar 14;8(1):4519
pubmed: 29540728
J Addict Med. 2011 Mar;5(1):1-8
pubmed: 21321675
Nat Rev Drug Discov. 2018 Sep;17(9):623-639
pubmed: 30116049
Int J Mol Sci. 2020 Apr 16;21(8):
pubmed: 32316328
Exp Clin Psychopharmacol. 2021 Apr 15;:
pubmed: 33856822